Mounjaro

Mounjaro shows 59% NASH resolution vs 17% placebo in clinical trials, with significant hepatic fat reduction beyond weight loss alone in NAFLD patients.

If you are getting ready to stop Mounjaro, one of the first decisions that comes up is whether to step down the dose gradually…

Mounjaro tiredness gets glossed over in the prescribing information, which lists fatigue at roughly 4 to 6 percent across the SURPASS trial program.

Six-month tirzepatide weight loss averages roughly 12 to 18 percent of starting body weight at the higher maintenance doses (10 to 15 mg weekly).

Yes. Tirzepatide is FDA-approved for chronic weight management in non-diabetic adults under the brand name Zepbound.

Introduction Tirzepatide (Zepbound® for obesity, Mounjaro® for diabetes) is currently the most effective FDA-approved weight loss medication, with 20.9% body weight reduction at 72…

Tirzepatide is the best obesity drug currently approved. It produced 20.9% mean weight loss at 72 weeks in SURMOUNT-1 (Jastreboff et al.

Introduction Patients switch between tirzepatide formulations and other GLP-1 drugs for several reasons: insurance changes, cost, side effect tolerance, plateau on the current drug,…

Tirzepatide is a peptide that degrades when exposed to heat, light, freezing, or repeated agitation.